Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Arrivent Biopharma Inc fell by 12.98m. Cash Flow from Financing totalled 42.86m or -- of revenues. In addition the company used 55.84m for operations while cash from investing was breakeven.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 8.85 |
---|---|
Tangible book value per share | 8.85 |
More ▼
Balance sheet in USDView more
Current ratio | 25.50 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼